iPSC-Derived RPE Therapy in AMD — PatSnap Eureka
iPSC-Derived Retinal Pigment Epithelium Therapy in Age-Related Macular Degeneration
Dry AMD—accounting for approximately 80% of AMD cases—has no approved cell-replacement therapy. iPSC-derived RPE transplantation is the leading regenerative strategy, now entering early-phase clinical investigation across multiple global programs.
Why RPE Replacement Is the Central Strategy for Dry AMD
The retinal pigment epithelium (RPE) monolayer sits between photoreceptors and the choriocapillaris, performing critical functions including photoreceptor outer segment phagocytosis, visual cycle retinoid recycling, ion and nutrient transport, and secretion of neurotrophic factors such as PEDF and VEGF isoforms. RPE dysfunction and death leads to secondary photoreceptor loss, establishing RPE replacement as a rational therapeutic target before the "point of no return" in disease progression.
Retrieved results from Yale University and Iran University of Medical Sciences both frame dry AMD as the primary unmet need, noting that anti-VEGF therapy stabilizes wet AMD but leaves dry AMD—representing the majority of patients—without a disease-modifying option. According to the World Health Organization, AMD is the leading cause of irreversible central vision loss in the elderly globally.
At the molecular level, a genomic fine-mapping study using iPSC-RPE identified rs943080 as a probable causal variant at the VEGFA locus through integrated ATAC-seq and ChIP-seq analysis, linking chromatin accessibility changes in RPE to AMD risk. An NEI/NIH study demonstrated repression of the SIRT1/PGC-1α pathway and mitochondrial disintegration in iPSC-RPE derived from AMD donors, implicating energy metabolism failure in AMD pathobiology. Canonical differentiation markers validated across multiple records include RPE65, MITF-A, Bestrophin (BEST1), RLBP, and ZO-1.
Four iPSC-RPE Delivery Strategies in AMD
From subretinal cell suspension injections to engineered scaffold implants, the field spans multiple delivery formats each with distinct engraftment, manufacturing, and clinical translation profiles.
Cell Suspension Subretinal Injection
The most frequently addressed modality across retrieved results delivers a bolus of differentiated RPE cells directly into the subretinal space. USC demonstrated long-term survival of iPSC-RPE monolayer cells at 11-month follow-up in immunodeficient RCS rats. UC Santa Barbara reported preserved photoreceptor morphology and function in retinal dystrophic rats. Aier Eye Institute showed reduced photoreceptor death in rd10 mice with detectable neurotrophic factor secretion by ELISA.
Preclinical → Early ClinicalScaffold-Based RPE Patch Implant
iPSC-RPE is engineered as a structured monolayer on biomaterial substrates—parylene C, polyester (PET) membranes—to recapitulate the polarized epithelial architecture of native RPE. Regenerative Patch Technologies reported 1-year follow-up data from a Phase 1/2a clinical trial in 16 subjects with advanced dry AMD receiving a parylene-mounted hESC-RPE implant. Scaffold design requirements including porosity, degradability, and Bruch's membrane compatibility are cited as essential for choriocapillaris reformation.
Phase 1/2a — Most AdvancedScaffold-Free iPSC-RPE Cell Sheets
RIKEN Center for Developmental Biology characterized hiPSC-RPE cell sheets optimized for clinical use without artificial scaffolds, demonstrating tight junction formation, polarized growth factor secretion, phagocytic function, and no immune rejection in autologous nonhuman primate transplants. Hitachi described an automated closed culture system for fabricating iPSC-RPE sheets, addressing operator variability and scalability constraints critical for commercial programs.
Preclinical → Clinical TranslationRetinal Sheet & Organoid Transplantation
A distinct modality targets end-stage disease where photoreceptors have been lost in addition to RPE. RIKEN demonstrated that mouse iPSC-derived retinal tissue transplanted into rd1 end-stage mice produced light-responsive behavior recorded via micro-electroretinography. University of Montreal reported subretinal transplantation of human iPSC-derived retinal sheets enriched in retinal progenitor and cone precursor cells using isogenic and hypoimmunogenic iPSC lines. This approach remains predominantly preclinical in the retrieved dataset.
Predominantly PreclinicalKey Metrics Across the iPSC-RPE AMD Pipeline
Quantitative signals from retrieved patent and literature records, visualised for rapid orientation across manufacturing, clinical, and molecular dimensions.
Differentiation Efficiency & Protocol Timeline
Rapid defined-factor protocols achieve >80% RPE differentiation efficiency in 14 days; single-cell transcriptomic mapping covered 25,718 cells during hESC-RPE differentiation.
Molecular Target Evidence Density in Retrieved Records
Relative frequency of molecular target citations across retrieved patent and literature records for iPSC-RPE AMD research.
iPSC-RPE Clinical Translation Timeline — Key Milestones
Progression of iPSC-RPE programs from first published transplantation data (2009) through Phase 1/2a clinical reporting (2021), based on retrieved records.
Differentiation Methods: The Core IP Battleground
Active patents are concentrated around upstream iPSC-to-RPE differentiation protocols. Freedom-to-operate analyses must account for method-of-production IP, not solely cell product IP.
Manufacturing scalability is the critical bottleneck for commercial iPSC-RPE programs
UC Santa Barbara estimates >10⁹ RPE cells annually required. Microcarrier technology and automated closed culture systems are cited as solutions in retrieved records.
Next-Generation Strategies Beyond Single-Cell RPE Replacement
Retrieved results signal several combination and next-generation strategies that extend beyond standard iPSC-RPE transplantation toward engineered, multi-cell, and manufacturing-optimised paradigms.
Combined RPE + Retinal Progenitor Cell Transplantation
A Vall d'Hebron Institut de Recerca study in RCS rats demonstrated that co-transplantation of hiPSC-derived RPCs and RPE cells was superior to either cell type alone in preserving retinal function at 12 weeks. UC Irvine explored co-grafts of hESC-derived retina organoids and RPE as a "total retina patch" for end-stage disease.
Hypoimmunogenic (Universal Donor) iPSC Lines
The University of Montreal study specifically employed hypoimmunogenic iPSC lines engineered for reduced immune rejection, representing an emerging direction to circumvent the cost and complexity of autologous cell manufacturing while avoiding lifelong immunosuppression.
Transcription Factor-Based Direct Reprogramming to iRPE
Kyoto University researchers described direct induction of RPE-like cells (iRPE) from human fibroblasts by overexpressing a combination of broad plasticity and lineage-specific transcription factors, bypassing full iPSC intermediates. Validated by scRNA-seq profiling and in vivo integration data, framed as potentially more cost-efficient than full iPSC reprogramming.
EMT-Resistant Engineered RPE
Tongji University signals that engineering transplanted RPE cells with Tet-on regulated c-Myc to confer TGF-β EMT resistance improves therapeutic outcomes in AMD rat models compared with standard iPSC-RPE, pointing toward a combination of cell engineering and transplantation as an emerging paradigm.
From First Rodent Transplant to Phase 1/2a Human Data
Retrieved results contain several explicit clinical translation signals confirming that multiple iPSC-RPE programs have entered human study. The most advanced clinical data point in this dataset is the Regenerative Patch Technologies Phase 1/2a trial reporting 1-year follow-up of 16 subjects with advanced non-neovascular AMD (geographic atrophy) receiving a parylene-mounted hESC-RPE implant. The primary endpoint was safety at 365 days; low-dose tacrolimus immunosuppression was used peri-implantation.
Multiple retrieved papers reference the first interventional clinical trial with autologous iPSC-derived RPE cells conducted at RIKEN/Kobe City Eye Hospital, Japan, as a clinical milestone. The Taipei Veterans General Hospital review discusses this trial's significance and subsequent shift toward allogeneic approaches now entering clinical study.
CHA Biotech (Korea) reported preliminary 1-year safety and tolerability data from four Asian patients—two dry AMD, two Stargardt disease—receiving subretinal hESC-RPE transplantation. No adverse proliferation or tumorigenicity was observed; three of four patients showed visual acuity improvement of 9–19 letters. The FDA and EMA regulatory frameworks for advanced therapy medicinal products are shaping the design of these early-phase programs globally.
Cell Cure Neurosciences (OpRegen) demonstrated functional efficacy in the longest preclinical study in this dataset—evaluated out to 60+ days post-transplantation in RCS rats across low, mid, and high doses—via optomotor tracking behavior and photoreceptor rescue histology, underpinning a clinical program. Explore how life sciences teams use PatSnap to track programs like OpRegen across the full development lifecycle.
Who Is Leading iPSC-RPE Innovation in AMD?
Innovation activity in this dataset is predominantly literature-driven (academic research papers), with a concentrated patent portfolio from a narrow set of institutional assignees focused on differentiation methods and RPE cell products.
Hadassit Medical Research Services (Hadassah Medical Center, Israel)
The most patent-prolific assignee in this dataset with at least 5 active filings across IL and EP jurisdictions (2012–2020). Claims center on Activin A-mediated directed differentiation with nicotinamide priming. Key markers cited include MITF-A, RPE65, and Bestrophin. Freedom-to-operate analysis for any iPSC-RPE program must address these method-of-production claims.
5+ active IL/EP filings · 2012–2020RIKEN Center for Developmental Biology (Kobe, Japan)
Multiple high-impact papers on iPSC-RPE sheet characterization, clinical-grade preparation, and retinal sheet transplantation in rodent models. Conducted the first autologous iPSC-RPE clinical trial at Kobe City Eye Hospital. Demonstrated no immune rejection in autologous nonhuman primate transplants and light-responsive behavior in rd1 end-stage mice via micro-electroretinography.
First autologous iPSC-RPE clinical trialUniversity of California Santa Barbara
Papers spanning initial iPS-RPE differentiation and transplantation (2009) through scalable microcarrier manufacturing and rapid directed differentiation protocols achieving >80% efficiency in 14 days. Estimates >10⁹ RPE cells annually required for the dry AMD patient population. Also contributed Phase 1/2a clinical trial data via collaboration with Regenerative Patch Technologies and Wilmer Eye Institute.
>80% efficiency · 14-day protocolUniversity of Minnesota (Twin Cities) & NEI/NIH
University of Minnesota AMD-specific iPSC-RPE modeling studies focused on mitochondrial dysfunction and drug response profiling, comparing AMD and non-AMD donors in response to AICAR, Metformin, and trehalose. NEI/NIH demonstrated repression of the SIRT1/PGC-1α pathway and mitochondrial disintegration in iPSC-RPE from AMD donors, establishing this axis as a therapeutic target for mitochondrial rescue strategies.
SIRT1/PGC-1α AMD disease modeliPSC-Derived RPE Therapy in AMD — key questions answered
iPSC-derived RPE therapy involves reprogramming patient or donor cells into induced pluripotent stem cells, then differentiating them into retinal pigment epithelium (RPE) cells for subretinal transplantation. The goal is to replace degenerated RPE in dry AMD—particularly geographic atrophy—for which no approved cell-replacement therapy currently exists.
Retrieved results identify three primary delivery formats: (1) cell suspension injected subretinally, (2) scaffold-based RPE patch implants on substrates such as parylene C or polyester membranes, and (3) scaffold-free RPE cell sheets. Each format offers different trade-offs between engraftment quality, surgical complexity, and scalability.
Key molecular targets identified across retrieved records include VEGFA (rs943080 causal variant), the SIRT1/PGC-1α mitochondrial biogenesis axis, TGF-β/EMT pathway, MERTK, RPE65, MITF-A, Bestrophin (BEST1), RLBP, ZO-1, and PEDF. These markers are used both to validate differentiation quality and as therapeutic targets.
Retrieved results confirm multiple programs have entered human study. Regenerative Patch Technologies reported 1-year follow-up from a Phase 1/2a clinical trial of an allogeneic hESC-RPE bioengineered implant in 16 subjects with advanced dry AMD. The first autologous iPSC-RPE clinical trial was conducted at RIKEN/Kobe City Eye Hospital, Japan. CHA Biotech reported preliminary 1-year safety data from four Asian patients showing visual acuity improvement of 9–19 letters in three of four subjects.
UC Santa Barbara estimates that more than 10⁹ RPE cells annually would be required to address the dry AMD patient population. Retrieved results identify microcarrier-based suspension culture and automated closed culture systems (Hitachi) as manufacturing innovations enabling high-density production and reduced operator variability—both prerequisites for commercially scalable allogeneic programs.
In this dataset, Hadassit Medical Research Services and Development Limited (Hadassah Medical Center, Israel) is the most patent-prolific assignee with at least 5 active filings across IL and EP jurisdictions claiming iPSC/PSC-derived RPE differentiation methods (2012–2020), centered on Activin A-mediated directed differentiation with nicotinamide priming. The Regents of the University of California hold an active EP patent claiming rapid high-yield RPE production from pluripotent cells using defined medium formulations.
Still have questions about the iPSC-RPE AMD pipeline? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About iPSC-RPEAccelerate Your iPSC-RPE AMD Research with AI-Powered Innovation Intelligence
Join 18,000+ innovators already using PatSnap Eureka to track cell therapy pipelines, analyse differentiation IP, and identify combination strategy opportunities across 2B+ patent and literature records.
References
- Potential of Induced Pluripotent Stem Cells (iPSCs) for Treating Age-Related Macular Degeneration (AMD) — Yale School of Medicine, 2016
- Human-induced pluripotent stem cells-derived retinal pigmented epithelium, a new horizon for cells-based therapies for age-related macular degeneration — Iran University of Medical Sciences, 2022
- Human iPSC-Derived Retinal Pigment Epithelium: A Model System for Prioritizing and Functionally Characterizing Causal Variants at AMD Risk Loci — University of California San Diego, 2019
- Human iPSC-derived retinal pigment epithelium: a model system for identifying and functionally characterizing causal variants at AMD risk loci — University of Edinburgh, 2018
- Repressed SIRT1/PGC-1α pathway and mitochondrial disintegration in iPSC-derived RPE disease model of age-related macular degeneration — National Eye Institute, NIH, 2016
- Induced retinal pigment epithelial cells with anti-epithelial-to-mesenchymal transition ability delay retinal degeneration — Tongji University School of Medicine, 2022
- Targeting Lipid Metabolism for the Treatment of Age-Related Macular Degeneration: Insights from Preclinical Mouse Models — University of Wisconsin–Madison, 2022
- Long-Term Transplant Effects of iPSC-RPE Monolayer in Immunodeficient RCS Rats — USC Ginsburg Institute for Biomedical Therapeutics, 2021
- Protective Effects of Human iPS-Derived Retinal Pigment Epithelium Cell Transplantation in the Retinal Dystrophic Rat — University of California Santa Barbara, 2009
- Protective effects of human iPS-derived retinal pigmented epithelial cells on retinal degenerative disease — Aier Eye Institute, 2020
- Pluripotent Stem Cells in Clinical Cell Transplantation: Focusing on Induced Pluripotent Stem Cell-Derived RPE Cell Therapy in Age-Related Macular Degeneration — Taipei Veterans General Hospital, 2022
- Characterization of Human Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium Cell Sheets Aiming for Clinical Application — RIKEN Center for Developmental Biology, 2014
- Fabricating retinal pigment epithelial cell sheets derived from human induced pluripotent stem cells in an automated closed culture system for regenerative medicine — Hitachi, Ltd., 2019
- Human iPSC derived disease model of MERTK-associated retinitis pigmentosa — CABIMER / Prince Felipe Research Center, 2015
- Rapid and Efficient Directed Differentiation of Human Pluripotent Stem Cells Into Retinal Pigmented Epithelium — UC Santa Barbara Neuroscience Research Institute, 2013
- iPSC-Derived Retina Transplants Improve Vision in rd1 End-Stage Retinal-Degeneration Mice — RIKEN Center for Developmental Biology, 2017
- Sub-retinal transplantation of human iPSC-derived retinal sheets: A promising approach for the treatment of macular degeneration — University of Montreal, 2023
- National Eye Institute (NEI/NIH) — U.S. National Institutes of Health
- World Health Organization — Age-Related Macular Degeneration Data
- U.S. Food and Drug Administration — Cell & Gene Therapy Regulatory Framework
- European Medicines Agency — Advanced Therapy Medicinal Products (ATMPs)
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.